Heterocyclic inhibitors of kinases
US7547711B2 · kind B2 · utility
0Cited by
12References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 8, 2006 |
| Grant date | Jun 16, 2009 |
| Priority date | — |
| Expiry date | Jun 22, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides compounds of formula Iand pharmaceutically acceptable salts thereof.The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.